When the Scientist Is an Agent: Governing AI Before It Reaches the IND
Ono Pharmaceutical's rollout of agentic AI to every discovery scientist exposes a governance gap that sits upstream of any device or wearable regulation.
life sciencesbriefings.
AI Drug Discovery's Capital Boom Sits Outside the Regulatory Perimeter, Not Ahead of It
Discovery-stage AI funding is surging, but the mismatch compliance leaders should track is structural, not a simple case of regulation lagging money.
The Traceability Debt Building Inside AI-Native Drug Discovery
Closed-loop AI discovery platforms are compressing timelines faster than biopharma governance functions can build the audit trail regulators will eventually demand.
AI Discovers Drugs. It Doesn't Approve Them.
AI drug discovery has drawn billions in investment but zero FDA approvals, and the bottleneck sponsors need to plan for is evidence, not speed.
The AI Drug Discovery Boom Is Outrunning Trial Execution
Generative AI is accelerating molecule design, but no AI-discovered drug has cleared trials, and regulators have yet to define how AI governs the trials themselves.
The Convergence Gap in AI Life Sciences Regulation
Regulators describe AI, digital health, and clinical trial law as converging, but FDA, UK, and Chinese actions show the frameworks are still moving on separate, misaligned tracks.
The Next Regulatory Question Isn't the Model. It's the Data It Rescued.
AI-driven reanalysis of failed clinical trials is producing new evidence outside the systems built to validate it, and GxP quality frameworks have not caught up.
AI Governance's Real Fault Line Is Classification, Not Geography
Divergence in AI rules across the US, EU, and China is driven less by geography than by conflicting definitions of what counts as a regulated AI function.
Complicated Is Not Complex: The Governance Gap in AI Drug Discovery
Drug discovery leaders are validating AI systems as if they were complicated, when the real risk is that they behave as complex, emergent systems.
EMA Moved First on AI. FDA Is Still Deciding How.
EMA's lifecycle-wide AI reflection paper and FDA's still-open genAI device rulemaking are running on different clocks, and neither is finished business for regulated buyers.
FDA's Other AI Track: Drug Development Gets Its Own Playbook
While FDA's device guidance draws attention, a parallel track for AI in early-phase clinical trials and drug development is quietly taking shape.
The Governance Debt Building in Drug Discovery AI
Regulatory frameworks are expanding toward AI in drug development, but the real exposure is a silent-failure risk that neither hype skeptics nor regulators are pricing in yet.
The Governance Gap Belongs to the Deployer, Not the Regulator
Hospitals and pharma functions adopting generative AI now carry governance obligations that device and drug frameworks were never built to cover.
Your Patients Are Uploading Health Data Into a Regulatory Gap
Life sciences firms building patient-facing AI tools are relying on a HIPAA and FDA perimeter that consumer health AI routinely sits outside.
The Architecture Decision Pharmacovigilance AI Cannot Defer
Cross-jurisdictional data rules are forcing pharma safety teams to choose between centralized and localized AI architectures before regulators force the choice for them.
Quantum-Classical AI Enters Drug Discovery, Validation Frameworks Don't
Quantum-enhanced generative AI is moving into drug discovery pipelines faster than GxP validation and data integrity practices can absorb it.
